Plasma pharmacokinetics and pharmacodynamics of alfaxalone in neonatal foals after an intravenous bolus of alfaxalone following premedication with butorphanol tartrate

SummaryPlasma pharmacokinetics, effect on coagulation parameters, and safety and tolerability of an intravenous infusion of ™REVASC before, during and after a DDAVP infusion were investigated.Twelve healthy volunteers were given an intravenous bolus dose followed by a constant rate four-hour infusion of ™REVASC. Fifteen-minute infusions of 0.9% saline and DDAVP were started two and three hours respectively after the start of the ™REVASC infusion.Plasma ™REVASC concentrations were not affected by either the saline or DDAVP infusion. ™REVASC infusion produced an increase in APTT which plateaued between 0.5 and 3 hours. After the DDAVP infusion there was a tendency towards a new lower plateau whilst the ™REVASC infusion continued. There were no serious adverse events or bleeding episodes throughout the study.In conclusion, the co-administration of intravenous DDAVP has no effect on the plasma pharmacokinetics of ™REVASC and partially reverses the ™REVASC-induced increase in APTT. This may represent a role for DDAVP in the partial reversal of anticoagulation induced by ™REVASC.

Download Full-text

Pharmacokinetics and pharmacodynamics of esmolol administered as an intravenous bolus

Clinical Pharmacology & Therapeutics ◽

10.1038/clpt.1987.19 ◽

1987 ◽

Vol 41 (1) ◽

pp. 112-117 ◽

Cited By ~ 35

Author(s):

Anthony L Sintetos ◽

James Hulse ◽

Edward L C Pritchett

Keyword(s):

Intravenous Bolus ◽

Pharmacokinetics And Pharmacodynamics

Download Full-text

Influence of Plasma Cholesterol and Triglyceride Concentrations and Eritoran (E5564) Micelle Size on its Plasma Pharmacokinetics and Ex Vivo Activity Following Single Intravenous Bolus Dose Into Healthy Female Rabbits

Pharmaceutical Research ◽

10.1007/s11095-007-9428-8 ◽

2007 ◽

Vol 25 (1) ◽

pp. 176-182 ◽

Cited By ~ 7

Author(s):

Kishor M. Wasan ◽

Verica Risovic ◽

Olena Sivak ◽

Stephen D. Lee ◽

Douglas X. Mason ◽

...

Keyword(s):

Bolus Dose ◽

Ex Vivo ◽

Plasma Cholesterol ◽

Intravenous Bolus ◽

Intravenous Bolus Dose ◽

Micelle Size ◽

Healthy Female ◽

Plasma Pharmacokinetics

Download Full-text

Plasma pharmacokinetics of alfaxalone in dogs after an intravenous bolus of Alfaxan-CD RTU

Veterinary Anaesthesia and Analgesia ◽

10.1111/j.1467-2995.2005.00264.x ◽

2006 ◽

Vol 33 (4) ◽

pp. 229-236 ◽

Cited By ~ 119

Author(s):

Pierre J Ferré ◽

Kirby Pasloske ◽

Ted Whittem ◽

Millagahamanda G Ranasinghe ◽

Qiang Li ◽

...

Keyword(s):

Intravenous Bolus ◽

Plasma Pharmacokinetics

Download Full-text

Plasma Pharmacokinetics and Pharmacodynamics of SSA3 in Rats

The FASEB Journal ◽

10.1096/fasebj.2021.35.s1.03992 ◽

2021 ◽

Vol 35 (S1) ◽

Author(s):

Benjamin Clements ◽

Cristina Peterson ◽

Kelley Kitto ◽

George Wilcox ◽

Carolyn Fairbanks

Keyword(s):

Pharmacokinetics And Pharmacodynamics ◽

Plasma Pharmacokinetics

Download Full-text

Pharmacokinetics and Pharmacodynamics of Propofol Microemulsion and Lipid Emulsion after an Intravenous Bolus and Variable Rate Infusion

Anesthesiology ◽

10.1097/01.anes.0000265151.78943.af ◽

2007 ◽

Vol 106 (5) ◽

pp. 924-934 ◽

Cited By ~ 48

Author(s):

Kye-Min Kim ◽

Byung-Moon Choi ◽

Si-Won Park ◽

Soo-Han Lee ◽

Lane V. Christensen ◽

...

Keyword(s):

Safety Profile ◽

Lipid Emulsion ◽

Causal Relation ◽

Dose Range ◽

Peak Effect ◽

Loss Of Consciousness ◽

Variable Rate ◽

Intravenous Bolus ◽

Pharmacokinetics And Pharmacodynamics ◽

Rate Infusion

Background The aim of this trial was to evaluate the induction and recovery characteristics of microemulsion propofol (Aquafol; Daewon Pharmaceutical Co., Ltd., Seoul, Korea). Pharmacokinetics, pharmacodynamics, and safety profile were investigated. Lipid emulsion propofol (Diprivan; AstraZeneca, London, United Kingdom) was used as a comparator. Methods Thirty-one healthy volunteers aged 20-79 yr were given an intravenous bolus of propofol 2 mg/kg, followed by variable rate infusion for 60 min. Each volunteer was studied twice with different formulations at an interval of 1 week. Arterial concentrations of propofol were measured, and Bispectral Index was used as a surrogate measure of propofol effect. The induction and recovery characteristics including bioequivalence were evaluated by noncompartmental analysis. The pharmacokinetics and pharmacodynamics were investigated using a population approach with mixed effects modeling. The rate, severity, and causal relation of adverse events were analyzed. Results Both formulations were bioequivalent. The observed time to peak effect after a bolus of both formulations was 1.5 min. Plasma concentration of propofol at loss of consciousness, time to loss of consciousness after a bolus, and time to recovery of consciousness after discontinuation of infusion did not show significant differences. The population pharmacokinetics and pharmacodynamics revealed a variety of differences between two formulations. Aquafol showed similar safety profile to Diprivan. Conclusions The efficacy and safety of Aquafol were not different from those of Diprivan within the dose range in this study.

Download Full-text

Pharmacokinetics and Pharmacodynamics of AC137 (25,28,29 Tripro-Amylin, Human) After Intravenous Bolus and Infusion Doses in Patients with Insulin-Dependent Diabetes

The Journal of Clinical Pharmacology ◽

10.1002/j.1552-4604.1996.tb04147.x ◽

1996 ◽

Vol 36 (1) ◽

pp. 13-24 ◽

Cited By ~ 43

Author(s):

Wayne A. Colburn ◽

Alan B. Gottlieb ◽

Joy Koda ◽

Orville G. Kolterman

Keyword(s):

Insulin Dependent Diabetes ◽

Intravenous Bolus ◽

Pharmacokinetics And Pharmacodynamics ◽

Insulin Dependent

Download Full-text

Cardiotoxicity with carfilzomib at doses greater than 27 mg/m2: A case series

Journal of Oncology Pharmacy Practice ◽

10.1177/1078155217729564 ◽

2017 ◽

Vol 25 (1) ◽

pp. 229-233 ◽

Cited By ~ 2

Author(s):

Gee Youn Kim ◽

Tania Ahuja ◽

John Papadopoulos ◽

Frank Cirrone

Keyword(s):

Heart Failure ◽

Adverse Effect ◽

Multiple Myeloma ◽

Proteasome Inhibitor ◽

Cardiac Toxicity ◽

Case Series ◽

Bolus Administration ◽

Intravenous Bolus ◽

Pharmacokinetics And Pharmacodynamics ◽

New Onset

Carfilzomib is a second-generation proteasome inhibitor that irreversibly inhibits chymotrypsin-like (CT-L) activities of the proteasome, and is indicated for relapsed or refractory multiple myeloma. Cardiotoxicity is a well-established adverse effect of carfilzomib. The extent of cardiac toxicity in the literature spans anywhere from palpitations to cardiac arrest, with the most commonly reported manifestation being new-onset or worsening heart failure. A pre-clinical study of the pharmacokinetics and pharmacodynamics of carfilzomib given via intravenous bolus or 30-minute infusion in rats showed that carfilzomib can strongly induce apoptosis and potently damage cardiac myocytes at clinically relevant concentrations. Moreover, the mortality rate with the bolus administration was 44% whereas the same dose administered as a 30-minute infusion did not result in mortality. There remains limited clinical data regarding the safety of carfilzomib at doses of 27–56 mg/m2 based on infusion times as these doses have not been well studied. This retrospective review was conducted to evaluate the safety of carfilzomib at doses >27 mg/m2 at all infusion times.

Download Full-text